|Biotech Due Diligence||
On Monday afternoon 3/3/2014, Synta Pharma issued a press release stating that CEO and co-founder Safi Bahcall had resigned effective immediately. As you may know, I have been covering SNTA and the development of their oncology drug candidate, the HSP90 inhibitor ganetespib, extensively. As such I thought I would offer a quick reaction to the news, and offer my answer to the question posed this morning by TheStreet's Adam Feuerstein "Will the company continue with the ongoing phase III study of ganetespib in non-small cell lung cancer? Or, is Bahcall's resignation the first step in a major overhaul of the company?"
Below you'll find a few scientific / medical articles that caught my eye recently and may be of general interest to the biotech investor and enthusiast. I call this feature the BiotechDueDiligence "Journal Watch."
You can also find a related feature on BDD's sister website. The journal watch editions posted there are more narrowly focused on therapeutic targets in oncology drug development (i.e., PI3K, ALK, HSP90, HER2, EGFR).
Sorry that there has been a bit of a lag between Biotech Reading Lists. Here is a new collection of links for the biotech enthusiast:
The Awesome Power of Risk
Michael Gilman (guest post on LifeSciVC blog)
New F.D.A. Nutrition Labels Would Make ‘Serving Sizes’ Reflect Actual Servings
Sabrina Tavernese (New York Times)
This Woman Invented a Way to Run 30 Lab Tests on Only One Drop of Blood
Caitlin Roper (Wired Science)
Interview with Elizabeth Holmes, founder of Theranos.
I never wanted to be a cancer expert, but then my wife got sick. A caregiver’s tale.
Saul Schwartz (Washington Post)
A Call to Rein in Phase III Trials
Derek Lowe (In the Pipeline)
Life Science Event Calendar
Useful link c/o @Comprendia
Your support is greatly appreciated